‍

‍

genOway’s presentation at the T-cell Therapeutics Summit, San Diego 2026

‍

Wednesday, June 24, 2026, 2 p.m.

‍

Session: Overcoming Therapeutic Resistance by Engineering Adaptive Immune Engagers to Transform Tumor Outcomes

Presenter: Kader Thiam, CSO & SVP – Discovery, Preclinical Models & Services

Title: "Advancing T Cell Engagers: Addressing Key Efficacy and Safety Challenges"

• Outlining genO-BRGSF-HIS mice: a CD34⁺-reconstituted model with functional human lymphoid and myeloid compartments, without side effects
• Highlighting the key contribution of myeloid cells in the assessment of cytokine release induced by TCE
• Evidencing the recruitment of human immune cells to tumor microenvironment, as well as their activation status